Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.53 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 4/20 | 0.47 |
| ▸ | MERTK | Q12866 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | LIPC | P11150 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067677 | 0.91 | MAP4K3 (0.53) | METMAP4K3TNK2DDB1CRBN | |
| SCHEMBL28762696 | 0.87 | MAP4K3 (0.62) | METMAP4K3TNK2AXLMERTK | |
| SCHEMBL28762743 | 0.87 | MAP4K3 (0.72) | METMAP4K3TNK2AXLMERTK | |
| SCHEMBL28762676 | 0.87 | MERTK (0.52) | METMAP4K3AXLMERTK | |
| SCHEMBL2330627 | 0.87 | MET (0.51) | METMAP4K3TNK2TTKDDB1 | |
| SCHEMBL28762670 | 0.86 | MAP4K3 (0.60) | METMAP4K3TNK2AXLMERTK | |
| SCHEMBL28762679 | 0.86 | MAP4K3 (0.61) | METMAP4K3TNK2AXLMERTK | |
| SCHEMBL28762729 | 0.86 | MAP4K3 (0.61) | METMAP4K3TNK2AXLMERTK | |
| SCHEMBL2386302 | 0.86 | MERTK (0.59) | METMAP4K3AXLMERTKFGFR1 | |
| SCHEMBL28762644 | 0.86 | MAP4K3 (0.59) | METMAP4K3TNK2AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | disclosed |
| WO-2022065962-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | 한국화학연구원 | 2022-03-31 | — | — | WO | disclosed |
| US-8017611-B2 | Pyridine and pyrazine derivatives -083 | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | MLKL, PCSK9, CTSA | MET 801/4885MAP4K3 1479/4885TNK2 1620/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | MET 2362/4885MAP4K3 102/4885TNK2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.